| Daniel Bergman, MD | |
|
619 19th St S, Birmingham, AL 35249-2541 | |
| (205) 934-4011 | |
| (205) 297-9411 |
| Full Name | Daniel Bergman |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 7 Years |
| Location | 619 19th St S, Birmingham, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053843169 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Alabama Hospital | Birmingham, AL | Hospital |
| Baptist Medical Center South | Montgomery, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Advanced Dermatology Of Alabama, Inc. | 2466866355 | 5 |
| University Of Alabama Health Services Foundation, Pc | 1951213107 | 2344 |
News Archive
While other studies have shown that muscle weakness as measured by grip strength is a predictor of unhealthy outcomes - including cardiovascular and metabolic diseases, disability and even early mortality - this is the first to do so for adolescent health over time, a Baylor University researcher said.
The interim data, from 205 volunteers in clinical trials in Kenya, Uganda and the United Kingdom, show that DNA.HIVA and MVA.HIVA are generally safe and well tolerated. However, the candidates' ability to elicit an anti-HIV cell-mediated immune response is poor, using currently accepted measures of immune response.
Despite the breadth of technological possibilities available, publishers and scientific journals have not provided adequate solutions for publication during fast moving emergencies. The UN International Strategy for Disaster Reduction has identified that "the sharing of research findings, lessons learned and best practices" are a priority in its Hyogo Framework for Action 2005-2015.
Researchers at the Aarhus University, Denmark, found that high baseline levels of ACE2 in plasma from COVID-19 patients are tied to a worse outcome in hospitalized patients. The study, which appeared on the pre-print server medRxiv, shows that measuring ACE2 levels in serum can help determine patients at a higher risk of developing severe illness from SARS-CoV-2 infection.
Cephalon, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved TREANDA (bendamustine hydrochloride) for Injection for the treatment of patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow disease, on March 20, 2008.
› Verified 8 days ago
| Entity Name | University Of Alabama Health Services Foundation, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093768723 PECOS PAC ID: 1951213107 Enrollment ID: O20031105000261 |
News Archive
While other studies have shown that muscle weakness as measured by grip strength is a predictor of unhealthy outcomes - including cardiovascular and metabolic diseases, disability and even early mortality - this is the first to do so for adolescent health over time, a Baylor University researcher said.
The interim data, from 205 volunteers in clinical trials in Kenya, Uganda and the United Kingdom, show that DNA.HIVA and MVA.HIVA are generally safe and well tolerated. However, the candidates' ability to elicit an anti-HIV cell-mediated immune response is poor, using currently accepted measures of immune response.
Despite the breadth of technological possibilities available, publishers and scientific journals have not provided adequate solutions for publication during fast moving emergencies. The UN International Strategy for Disaster Reduction has identified that "the sharing of research findings, lessons learned and best practices" are a priority in its Hyogo Framework for Action 2005-2015.
Researchers at the Aarhus University, Denmark, found that high baseline levels of ACE2 in plasma from COVID-19 patients are tied to a worse outcome in hospitalized patients. The study, which appeared on the pre-print server medRxiv, shows that measuring ACE2 levels in serum can help determine patients at a higher risk of developing severe illness from SARS-CoV-2 infection.
Cephalon, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved TREANDA (bendamustine hydrochloride) for Injection for the treatment of patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow disease, on March 20, 2008.
› Verified 8 days ago
| Entity Name | Christopher B Harmon Md Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477708642 PECOS PAC ID: 9436211463 Enrollment ID: O20081229000234 |
News Archive
While other studies have shown that muscle weakness as measured by grip strength is a predictor of unhealthy outcomes - including cardiovascular and metabolic diseases, disability and even early mortality - this is the first to do so for adolescent health over time, a Baylor University researcher said.
The interim data, from 205 volunteers in clinical trials in Kenya, Uganda and the United Kingdom, show that DNA.HIVA and MVA.HIVA are generally safe and well tolerated. However, the candidates' ability to elicit an anti-HIV cell-mediated immune response is poor, using currently accepted measures of immune response.
Despite the breadth of technological possibilities available, publishers and scientific journals have not provided adequate solutions for publication during fast moving emergencies. The UN International Strategy for Disaster Reduction has identified that "the sharing of research findings, lessons learned and best practices" are a priority in its Hyogo Framework for Action 2005-2015.
Researchers at the Aarhus University, Denmark, found that high baseline levels of ACE2 in plasma from COVID-19 patients are tied to a worse outcome in hospitalized patients. The study, which appeared on the pre-print server medRxiv, shows that measuring ACE2 levels in serum can help determine patients at a higher risk of developing severe illness from SARS-CoV-2 infection.
Cephalon, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved TREANDA (bendamustine hydrochloride) for Injection for the treatment of patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow disease, on March 20, 2008.
› Verified 8 days ago
| Entity Name | Cooper Green Mercy Health Services Authority An Affiliate Of Uab |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366073108 PECOS PAC ID: 0840629473 Enrollment ID: O20200402003238 |
News Archive
While other studies have shown that muscle weakness as measured by grip strength is a predictor of unhealthy outcomes - including cardiovascular and metabolic diseases, disability and even early mortality - this is the first to do so for adolescent health over time, a Baylor University researcher said.
The interim data, from 205 volunteers in clinical trials in Kenya, Uganda and the United Kingdom, show that DNA.HIVA and MVA.HIVA are generally safe and well tolerated. However, the candidates' ability to elicit an anti-HIV cell-mediated immune response is poor, using currently accepted measures of immune response.
Despite the breadth of technological possibilities available, publishers and scientific journals have not provided adequate solutions for publication during fast moving emergencies. The UN International Strategy for Disaster Reduction has identified that "the sharing of research findings, lessons learned and best practices" are a priority in its Hyogo Framework for Action 2005-2015.
Researchers at the Aarhus University, Denmark, found that high baseline levels of ACE2 in plasma from COVID-19 patients are tied to a worse outcome in hospitalized patients. The study, which appeared on the pre-print server medRxiv, shows that measuring ACE2 levels in serum can help determine patients at a higher risk of developing severe illness from SARS-CoV-2 infection.
Cephalon, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved TREANDA (bendamustine hydrochloride) for Injection for the treatment of patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow disease, on March 20, 2008.
› Verified 8 days ago
| Entity Name | Advanced Dermatology Of Alabama, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538773775 PECOS PAC ID: 2466866355 Enrollment ID: O20210204002577 |
News Archive
While other studies have shown that muscle weakness as measured by grip strength is a predictor of unhealthy outcomes - including cardiovascular and metabolic diseases, disability and even early mortality - this is the first to do so for adolescent health over time, a Baylor University researcher said.
The interim data, from 205 volunteers in clinical trials in Kenya, Uganda and the United Kingdom, show that DNA.HIVA and MVA.HIVA are generally safe and well tolerated. However, the candidates' ability to elicit an anti-HIV cell-mediated immune response is poor, using currently accepted measures of immune response.
Despite the breadth of technological possibilities available, publishers and scientific journals have not provided adequate solutions for publication during fast moving emergencies. The UN International Strategy for Disaster Reduction has identified that "the sharing of research findings, lessons learned and best practices" are a priority in its Hyogo Framework for Action 2005-2015.
Researchers at the Aarhus University, Denmark, found that high baseline levels of ACE2 in plasma from COVID-19 patients are tied to a worse outcome in hospitalized patients. The study, which appeared on the pre-print server medRxiv, shows that measuring ACE2 levels in serum can help determine patients at a higher risk of developing severe illness from SARS-CoV-2 infection.
Cephalon, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved TREANDA (bendamustine hydrochloride) for Injection for the treatment of patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow disease, on March 20, 2008.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Daniel Bergman, MD Po Box 55310, Birmingham, AL 35255-5310 Ph: (205) 731-9701 | Daniel Bergman, MD 619 19th St S, Birmingham, AL 35249-2541 Ph: (205) 934-4011 |
News Archive
While other studies have shown that muscle weakness as measured by grip strength is a predictor of unhealthy outcomes - including cardiovascular and metabolic diseases, disability and even early mortality - this is the first to do so for adolescent health over time, a Baylor University researcher said.
The interim data, from 205 volunteers in clinical trials in Kenya, Uganda and the United Kingdom, show that DNA.HIVA and MVA.HIVA are generally safe and well tolerated. However, the candidates' ability to elicit an anti-HIV cell-mediated immune response is poor, using currently accepted measures of immune response.
Despite the breadth of technological possibilities available, publishers and scientific journals have not provided adequate solutions for publication during fast moving emergencies. The UN International Strategy for Disaster Reduction has identified that "the sharing of research findings, lessons learned and best practices" are a priority in its Hyogo Framework for Action 2005-2015.
Researchers at the Aarhus University, Denmark, found that high baseline levels of ACE2 in plasma from COVID-19 patients are tied to a worse outcome in hospitalized patients. The study, which appeared on the pre-print server medRxiv, shows that measuring ACE2 levels in serum can help determine patients at a higher risk of developing severe illness from SARS-CoV-2 infection.
Cephalon, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved TREANDA (bendamustine hydrochloride) for Injection for the treatment of patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow disease, on March 20, 2008.
› Verified 8 days ago
Callie Roberts Hill, Dermatology Medicare: Medicare Enrolled Practice Location: 1927 1st Ave N, Birmingham, AL 35203 Phone: 205-933-0987 Fax: 205-930-1750 | |
Carly Elston, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 500 22nd St S, Birmingham, AL 35233 Phone: 205-934-9999 | |
Tiffany Mayo, Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1717 6th Ave S, Birmingham, AL 35233 Phone: 800-822-8816 | |
Carlton Phillips, Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2100 16th Ave S, Birmingham, AL 35205 Phone: 205-933-0987 Fax: 205-930-1758 | |
Katherine Flanagan, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 813 Shades Creek Pkwy, Suite 205, Birmingham, AL 35209 Phone: 205-578-1799 Fax: 205-578-3158 | |
Vijay Balakrishnan, MD Dermatology Medicare: Medicare Enrolled Practice Location: 510 20th St S Ste 858, Birmingham, AL 35233 Phone: 205-934-5188 |